Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.
Bräutigam K, Bauerschlag DO, Weigel MT, Biernath-Wüpping J, Bauknecht T, Arnold N, Maass N, Meinhold-Heerlein I. Bräutigam K, et al. Among authors: bauknecht t. Transl Oncol. 2009 Aug 18;2(3):164-73. doi: 10.1593/tlo.09121. Transl Oncol. 2009. PMID: 19701501 Free PMC article.
Gene therapy of ovarian cancer.
Bauknecht T, Meinhold-Heerlein I. Bauknecht T, et al. Curr Womens Health Rep. 2002 Feb;2(1):39-46. Curr Womens Health Rep. 2002. PMID: 12112982 Review.
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: bauknecht t. Oncogene. 2005 Feb 3;24(6):1053-65. doi: 10.1038/sj.onc.1208298. Oncogene. 2005. PMID: 15558012
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: bauknecht t. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66. doi: 10.1158/1078-0432.CCR-06-0691. Clin Cancer Res. 2007. PMID: 17255266
Evaluation of methods to detect p53 mutations in ovarian cancer.
Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, Bauknecht T. Meinhold-Heerlein I, et al. Among authors: bauknecht t. Oncology. 2001;60(2):176-88. doi: 10.1159/000055316. Oncology. 2001. PMID: 11244334
G-CSF receptor expression in ovarian cancer.
Ninci EB, Brandstetter T, Meinhold-Heerlein I, Bettendorf H, Sellin D, Bauknecht T. Ninci EB, et al. Among authors: bauknecht t. Int J Gynecol Cancer. 2000 Jan;10(1):19-26. doi: 10.1046/j.1525-1438.2000.99076.x. Int J Gynecol Cancer. 2000. PMID: 11240647
112 results